Buscar
Mostrando ítems 1-10 de 50
Burning mouth syndrome responsive to pramipexol
(SPRINGER, 2008)
Burning mouth syndrome (BMS) is characterized by burning discomfort or pain in otherwise normal oral mucosa. It is usually refractory. Treatment modalities are scarce. Herein we report one case of primary disabling BMS, ...
Hypersexuality associated to pramipexole in the treatment of parkinsonian symptoms: presentation of 3 cases and review of the literatureHipersexualidad asociada a pramipexol, en el tratamiento de síntomas parkinsonianos: revisión de la literatura, a propósito de 3 casos
(Universidad Nacional Mayor de San Marcos, Facultad de Medicina Humana, 2010)
Contrasting gene expression patterns induced by levodopa and pramipexole treatments in the rat model of Parkinson's disease
(Pergamon-Elsevier Science Ltd, 2015-05)
Whether the treatment of Parkinson's disease has to be initiated with levodopa or a D2 agonist like pramipexole remains debatable. Levodopa is more potent against symptoms than D2 agonists, but D2 agonists are less prone ...
Hipersexualidad asociada a pramipexol, en el tratamiento de síntomas parkinsonianos: revisión de la literatura, a propósito de 3 casos
(Universidad Nacional Mayor de San Marcos. Facultad de Medicina, 2010)
Evaluación de los efectos antioxidantes del pramipexol en un modelo de rotenona
(Benemérita Universidad Autónoma de Puebla, 2019-12)
"El pramipexol es un agonista de la subfamilia de receptores de dopamina D2 con afinidad
preferencial por el subtipo D3. Desde 1998, este fármaco ha sido indicado para el tratamiento
sintomatológico de la Enfermedad ...
Efectos y adaptaciones inducidos por el tratamiento prolongado con agonistas dopaminérgicos en un modelo animal de la enfermedad de ParkinsonEfects and adaptations induced by long term treatment with dopamine agonists in an animal model of parkinson’s disease
(Facultad de Ciencias Exactas y Naturales. Universidad de Buenos Aires, 2011)
Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients
(Taylor & Francis, 2014-03)
Introduction: Dopamine agonists (DAs) are frequently used to treat early or advanced Parkinson’s disease (PD) patients. They have been shown to be efficacious for the treatment of motor symptoms and for delaying levodopa-induced ...